June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The use of mini-plasmids free of antibiotic resistance markers for a gene therapeutical approach to treat AMD
Author Affiliations & Notes
  • Nina Harmening
    Service d'Ophtalmologie, Hôptaux universitaire de Genève, Geneva, Switzerland
  • Martina Kropp
    Service d'Ophtalmologie, Hôptaux universitaire de Genève, Geneva, Switzerland
  • Sandra Johnen
    Department of Ophthalmology, University hospital RWTH Aachen, Aachen, Germany
  • Corinne Marie
    Unité de Technologies Chimiques et Biologiques pour la Santé, INSERM U1022 - CNRS UMR8258, Paris, France
  • Daniel Scherman
    Unité de Technologies Chimiques et Biologiques pour la Santé, INSERM U1022 - CNRS UMR8258, Paris, France
  • Zsuzsanna Izsvák
    Max Delbrück Center for Molecular Medicine, Berlin, Germany
  • Gabriele Thumann
    Service d'Ophtalmologie, Hôptaux universitaire de Genève, Geneva, Switzerland
  • Footnotes
    Commercial Relationships Nina Harmening, None; Martina Kropp, None; Sandra Johnen, None; Corinne Marie, None; Daniel Scherman, None; Zsuzsanna Izsvák, None; Gabriele Thumann, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 2325. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nina Harmening, Martina Kropp, Sandra Johnen, Corinne Marie, Daniel Scherman, Zsuzsanna Izsvák, Gabriele Thumann; The use of mini-plasmids free of antibiotic resistance markers for a gene therapeutical approach to treat AMD. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):2325.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: For the treatment of exudative age-related macular degeneration (AMD), we developed a protocol to electroporate pigment epithelial cells with the anti-angiogenic and neuroprotective pigment epithelium-derived factor (PEDF). The ultimate goal of our investigations is the transplantation of autologous, transfected cells into the subretinal space, where the secreted PEDF inhibits neovascularization. For stable and efficient transfection, we use the non-viral Sleeping Beauty (SB100X) transposon system, which enables integration of the gene into the host cell’s genome. To further enhance the transfection efficiency and safety characteristics of the procedure, a new generation of vectors free of antibiotic resistance markers (pFAR4) was evaluated.

Methods: Primary pigment epithelial cells were co-transfected with a SB100X transposase-encoding plasmid and a transposon plasmid encoding the PEDF or the Venus gene using electroporation protocols. Analogous pT2 transposon plasmids carrying an ampicillin-resistance gene were compared to pFAR4-plasmids. Fluorescence of Venus-transfected cells was measured by image-based cytometry and PEDF secretion was evaluated by Western blot analysis and quantified by ELISA.

Results: Transfection of 10’000 cells with the Venus-encoding plasmids resulted in higher transfection efficiencies using pFAR4-ITRs-CAGGS-Venus (29.1%±5.28) compared to pT2-CAGGS-Venus (9.7%±2.00). Non-transfected control cells secreted 0.3±0.05 ng PEDF/h/104 cells, cells transfected with the pT2-CMV-PEDF transposon plasmid secreted 4.3±4.05 ng PEDF/h/104 cells, and cells transfected with pFAR4-ITRs-CMV-PEDF secreted 11.1±8.12 ng PEDF/h/104 cells, a 2.5-fold increase compared to cells transfected with pT2-CMV-PEDF. Western Blot analysis highlighted these results and showed higher PEDF secretion in the pFAR4-transfected cells.

Conclusions: The present work demonstrates that using pFAR4 plasmids augments PEDF secretion while simultaneously enhancing the safety of the approach. The avoidance of antibiotic resistance markers is a crucial step towards the clinical use of the SB100X transposon system; in a phase Ib/IIa clinical trial, planned for 2015, autologous pigment epithelial cells will be transfected with the PEDF gene and re-transplanted subretinally as novel therapy for exudative AMD using pFAR4 miniplasmids together with the SB100X transposon system.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×